FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test offers clinicians a crucial tool for managing hypertensive disorders of pregnancy, with potential significant cost savings and improved patient ...
Next-generation column technology enhances efficiency, expands recurring revenue potential, and strengthens Trinity Biotech’s competitive position in the $2B+ HbA1c market DUBLIN, Dec. 15, 2025 (GLOBE ...
DUBLIN, Ireland, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech (TRIB), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, today ...
DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...
Trinity Biotech (TRIB) has released an update. Trinity Biotech has made a strategic investment of $2.5 million to acquire a 12.5% equity stake in Novus Diagnostics, a company developing rapid sepsis ...
Company advances its mission to deliver next-generation diabetes management solutions and expand global market penetration Next-generation column technology enhances efficiency, expands recurring ...
Trinity Biotech will make a $1.5M convertible note investment in imaware™ alongside lead investor McNair Interests to accelerate partnership commercialisation efforts with a pipeline of payor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results